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doi:10.1016/j.kjms.2011.10.011Abstract The 5a-reductase type 2 deficiency is a rare autosomal recessive 46,XY disorder
of sex development caused by the mutated 5a-reductase type 2 (SRD5A2) gene. In this
disease, defective conversion of testosterone to dihydrotestosterone leads to variable
presentations of male ambiguous genitalia during fetal development. The most crucial clin-
ical decision for the affected individual is proper gender assignment; therefore, a prompt
and correct diagnosis is important. In this present study, we report a normal male karyotype
manifesting microphallus, bifid scrotum/labia majora with bilateral palpable gonads, and
a blind-ended pseudovagina. The mutation analysis of the SRD5A2 gene revealed one novel
C to T transition changing glutamine to a stop codon at codon 71 (p.Q71X) in exon 1 and one
known G to A transition changing arginine to glutamine at codon 227 (p.R227Q) in exon 4.
The p.Q71X mutation presumably results in a truncated protein, while the p.R227Q mutation
is conceived to impair enzyme function and has been reported in patients of East Asian
descent. This report demonstrates the essential role of hormonal and molecular studies
for genetic counseling and gender assignment in males with pseudovaginal disorder of sex
development, and our report helps identify a novel SRD5A2 gene mutation in the Taiwanese
population.
Copyright ª 2012, Elsevier Taiwan LLC. All rights reserved.nt of Pediatrics, National
Shengli Road, Tainan 704,
u.tw (S.-J. Lin).
vier Taiwan LLC. All rights reservIntroduction
The 5a-reductase type 2 deficiency (OMIM number 264600) is
an autosomal recessive disorder characterized by aberrant
male sex development. Affected males usually present at
birth with ambiguous external genitalia, such as perineo-
scrotal hypospadias, pseudovagina, microphallus, anded.
232 M.-C. Tsai et al.cryptorchidism [1]. However, a wide variety of clinical
phenotypes range from complete feminization to under-
masculinization or isolated infertility. Deficiency of this key
enzyme fails to convert testosterone to dihydrotestosterone
in a sufficient amount for normal differentiation of male
genitalia during fetal development. Dihydrotestosterone
also modulates psych-orientation of the prenatal human
brain and mediates numerous critical steps of masculiniza-
tion at puberty. Hence, residual activity of abnormal 5a-
reductase type 2 enzyme leads to variable degrees of viri-
lization at birth and has an impact on lifelong psychological
functioning [2].
Several forms of 46,XYdisorders of sex differentiationmay
share similar clinical presentations with 5a-reductase type 2
deficiency. Differential diagnosis with partial androgen
insensitivity and 17b-hydroxysteroid dehydrogenase defi-
ciency sometimes can be difficult and may be facilitated on
the basis of a biochemical evaluation [3]. After human cho-
rionic gonadotropin (hCG) stimulation, hormonal measure-
ment of serum testosterone-to-androstenedione ratio
determines a diagnosis of 17b-hydroxysteroid dehydrogenase
deficiency,while serumtestosterone-to-dihydrotestosterone
ratio testifies a diagnosis of 5a-reductase type 2 deficiency
[4]. An abnormally high baseline and hCG-stimulated testos-
terone-to-dihydrotestosterone ratio is the hallmark of 5a-
reductase type 2 deficiency [1,5,6]. However, unremarkable
elevated level of testosterone-to- dihydrotestosterone ratio
after hCG stimulation does not refute this diagnosis, espe-
cially in patients with partially dysfunctional enzyme activity
[7,8].
The 5a-reductase type 2 (SRD5A2) gene, which encodes
5a-reductase type 2 enzyme, is located on chromosome
2p23. The coding region consists of 5 exons, which are
translated into a 254-amino acid protein [9]. To date, more
than 50 mutations have been identified in different ethnic-
ities in previous studies. Scattered throughout the gene,
missense mutations are most common, while some are
nonsense or splice-junction mutations [5,8,10e14]. Nucleo-
tide or entire deletion of the SRD5A2 gene has also been
described [15]. Accordingly, molecular analysis presently
provides adjunct evidence of the definite diagnosis in the
diversity of phenotypic features [16].
Previously, 5a-reductase type 2 deficiency was often
suggested merely on the basis of clinical and biochemical
features [17]. The characteristics of SRD5A2 gene muta-
tions pertaining to the Taiwanese population were scarcely
known. In this article, we confirmed the diagnosis by virtue
of a molecular analysis and reported a novel SRD5A2
mutation in a newborn with ambiguous genitalia.Figure 1. (A) Ambiguous genitalia with bilateral palpable
gonads in bifid scrotum/labia majora, a clitoris-like phallus
measuring 1.3 cm with a urethral orifice on the tip of under-
developed glans, and a blind-pouched vagina at 1 month of
age; (B) enlargement of the microphallus measuring 2.8 cm
along with a pseudovagina and gonads in bifid labioscrotal folds
at 6 months of age.Case report
This patient was born at the 38th gestational week with an
uneventful perinatal history. The parents were of Taiwa-
nese origin without consanguineous history, and their
previous two children did not have any specific problems.
At birth, the patient manifested ambiguous external
genitalia. On physical examination, bilateral gonads were
palpable in bifid scrotum/labia majora. A clitoris-like
phallus measured 1.3 cm, and there was a urethral
orifice on the tip of underdeveloped glans. Inferior to themicrophallus was a blind-pouched vagina (Fig. 1A). Pelvic
ultrasonography revealed absence of Mullerian remnants.
The serum hormonal profile showed an elevated total
testosterone level of 2.13 ng/dL (normal range,
0.1e0.75 ng/dL), and a 17-hydroxyprogesterone level of
dried blood spot on filter paper was 1.7 ng/ml (normal
range, 0.4e4.3 ng/ml). The serum dihydrotestosterone
level was not available. The chromosome study, performed
on peripheral blood lymphocytes, showed a normal male
46,XY karyotype. Since the clinical presentations and
endocrine investigations were suggestive of 5a-reductase
type 2 deficiency or partial androgen insensitive syndrome,
genetic analysis of these two disorders were initiated
immediately under his parents’ informed consent. hCG
stimulation test was not performed in this case. On the
basis of his final diagnosis, male gender was assigned after
discussion with his family. Accordingly, he received
a monthly injection of testosterone cypionate 50 mg and
his penile length increased from 1.3 to 2.8 cm at 6 months
of age (Fig. 1B).
Table 1 Oligonucleotide primers used for polymerase chain reaction amplification of the SRD5A2 gene (annealing
temperature Z 58 C).
Exon Forward (50/ 30) Backward (50 / 30) Product size (bp)
1 GCAGCGGCCACCGGCGAGG AGCAGGGCAGTGCGCTGCACT 358
2 TGAATCCTAACCTTTCCTCCC AGCTGGGAAGTAGGTGAGAA 235
3 TGTGAAAAAAGCACCACAATCT CAGGGAAGAGTGAGATCTGG 208
4 TGATTGACCTTCCGATTCTT TGGAGAAGAAGAAAGCTACGT 232
5 TCAGCCACTGCTCCATTATAT CAGTTTTCATCAGCATTGTGG 166
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Molecular analysis of the androgen receptor (AR) gene and
SRD5A2 gene was applied on peripheral blood lymphocytes
collected in EDTA (Ethylenediaminetetraacetic acid)-
containing tubes. Genomic DNA was extracted according
to the manufacturer’s instructions (Genomic DNAFigure 2. (A) Automated sequencing of the SRD5A2 gene revealed
codon 71 (Q71X); and (B) one known G to A transition resulting inExtraction Kit, RBC Bioscience Corp., Taiwan). For poly-
merase chain reaction (PCR) amplification of SRD5A2
gene, five sets of primers spanning all five exons and the
flanking splice sites were used (Table 1). Briefly, approx-
imately 50 ng of genomic DNA, 10 pmol of each primer, 5
mmol of each deoxyribonucleoside triphosphate, 0.2 U of
pro Taq DNA polymerase (Promega, Madison, WI, USA) andone novel C to T transition resulting in a nonsense mutation at
a missense mutation at codon 227 (R227Q).
234 M.-C. Tsai et al.PCR buffer were contained in a total volume of 50 mL. The
amplification conditions were denaturation at 95C for
5 minutes, followed by 35 cycles of amplification with
denaturation at 94C for 40 seconds, annealing at 58C for
40 seconds and elongation at 72C for 40 seconds, and
finally an extension at 72C for 10 minutes. The PCR
products were subsequently examined on 2% agarose and
subjected to direct automated sequencing using the ABI
310 Genetic Analyzer (Applied Biosystems). The mutation
analysis of the SRD5A2 gene revealed a compound
heterozygous mutation: one novel C to T transition
changing glutamine to a stop codon at codon 71 (p.Q71X)
in exon 1 and one known G to A transition changing argi-
nine to glutamine at codon 227 (p.R227Q) in exon 4.
(Fig. 2). No mutation was identified in the AR gene.Discussion
Around the world, more than 50 mutations have been re-
ported in the literature, but little was known about the
molecular characterization of SRD5A2 gene among Taiwa-
nese patients receiving the diagnosis on the basis of
biochemical results. Our patient was a compound heterozy-
gote of one novel (p.Q71X) and one known (p.R227Q) muta-
tions. The p.Q71Xmutation has not been described yet in the
literature. Harbored in exon 1 SRD5A2 gene, the shift of
glutamine to a premature stop codon is presumed to give rise
to a drastically truncated mutant protein. Conceivably, the
activity of 5a-reductase type 2 enzyme is abolished and
results in undervirilization. Nonetheless, compound hetero-
zygosity with a missense mutation might reduce the severity
by producing a partially functional enzyme. The p.R227Q
substitution has been previously reported in two brothers of
Vietnamese origin [8]. The elder brother presented with
scrotal hypospadia, a bifid scrotum with bilateral descended
testes, and a small penis, while his younger brother merely
had a small penis. Both of them were homozygotes of
p.R227Q/p.R227Q mutation. Compound hetreozygotes
of p.R227Q mutation have also been reported in patients of
Chinese and Japanese origin [18e20]. These individuals
presented diversely, with a pseudovaginal perineoscrotal
hypospadia to simply a micropenis. The affected exon 4 of
SRD5A2 gene, where this mutation locates, may be respon-
sible for the decreased affinity of this enzyme binding with
nicotinamide adenine dinucleotide phosphate hydrogen and
causes enzyme dysfunction [1,10]. In vitro reduction of the
enzyme activity has been proven in some patients carrying
mutation from arginine to glutamine [21]. The observation of
recurrent mutations in different ethnic groups may reflect
a mutational hot spot in the SRD5A2 gene or a common
founder gene from East Asian ancestry.
Although the degree of virilization was enormously vari-
able in reported cases of SRD5A2 mutations, our patient
presented with a typical clitoris-like microphallus with
bilateral palpable gonads in the bifid scrotum/labia majora
and a pseudovagina. These symptoms of aberrant sex
development are similar to partial androgen insensitivity and
17b-hydroxysteroid dehydrogenase deficiency. Under such
circumstances, elevated testosterone/dihydrotestosterone
ratio after hCG stimulation for 3 consecutive days was
traditionally diagnostic of a 5a-reductase type 2 deficiency.Molecular diagnosis came recently into clinical practice
with an emphasis on timely genetics and inheritance infor-
mation. Our experience demonstrated that the detection of
SRD5A2 mutations provided a helpful alternative approach
in patients with suggestive clinical presentations and
biochemical values.
Rearing a child with intersex generally brings pressures to
the parents in a Taiwanese cultural context. Previous reports
have also shown the transition of masculine behavior and
male psychosexual orientation in some patients with 5a-
reductase type 2 deficiency assigned as females since their
infancy [22]. It is postulated that prenatal androgen expo-
sure may exert its masculinizing influence on the develop-
mental brain with regard to sexual differentiation [23]. After
a definite diagnosis, genetic counseling and discussion of
gender assignment were promptly given to his parents. This
patient was decided to be raised as a male under his parents’
informed consent, taking into account the phenotypic
features and molecular cause, before administration of
testosterone injections. The importance of a timely and
correct diagnosis as well as a full discussion of the bio-
psycho-social factors with regard to the decision of gender
assignment in patients with SRD5A2 mutation is therefore
highly advocated.Conclusion
We report one known and one novel mutation of SRD5A2 gene
in a Taiwanese 46, XY newborn with ambiguous external
genitalia. Our data delineated the genotype-phenotype
relation of the SRD5A2 gene mutation and underlined the
importance of a genetic diagnosis and counseling with regard
to gender assignment. More than 50 mutations have been
identified among the wide-ranging coding regions of the
SRD5A2 gene. However, the genotype-phenotype correlation
is not well described yet. Future investigation on a molecular
basis may provide new insight and approaches to 5a-reduc-
tase type 2 deficiency. Themolecular characterization of the
SRD5A2 gene among Taiwanese patients will also clarify its
epidemiologic distribution and frequency.Acknowledgments
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